Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

2.

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

3.

healthy despite having advanced cancer.

4.

Breast awareness: What to look for in your self-exam

5.

Significant differences in breast cancer care still exist, but surgeons can change.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot